Mersana Therapeutics Stock Performance
| MRSN Stock | USD 2.00 0.04 1.96% |
On a scale of 0 to 100, Mersana Therapeutics holds a performance score of 8. The company secures a Beta (Market Risk) of 4.03, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Mersana Therapeutics will likely underperform. Please check Mersana Therapeutics' value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Mersana Therapeutics' current price movements will revert.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Mersana Therapeutics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Mersana Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 129.4 M |
Mersana |
Mersana Therapeutics Relative Risk vs. Return Landscape
If you would invest 149.00 in Mersana Therapeutics on August 28, 2024 and sell it today you would earn a total of 51.00 from holding Mersana Therapeutics or generate 34.23% return on investment over 90 days. Mersana Therapeutics is currently generating 0.6812% in daily expected returns and assumes 6.6737% risk (volatility on return distribution) over the 90 days horizon. In different words, 59% of stocks are less volatile than Mersana, and 87% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Mersana Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mersana Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Mersana Therapeutics, and traders can use it to determine the average amount a Mersana Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1021
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MRSN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.67 actual daily | 59 59% of assets are less volatile |
Expected Return
| 0.68 actual daily | 13 87% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 8 92% of assets perform better |
Based on monthly moving average Mersana Therapeutics is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mersana Therapeutics by adding it to a well-diversified portfolio.
Mersana Therapeutics Fundamentals Growth
Mersana Stock prices reflect investors' perceptions of the future prospects and financial health of Mersana Therapeutics, and Mersana Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mersana Stock performance.
| Return On Equity | -2.13 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (2.14) % | ||||
| Operating Margin | (0.96) % | ||||
| Current Valuation | 128.34 M | ||||
| Shares Outstanding | 123.53 M | ||||
| Price To Earning | (0.98) X | ||||
| Price To Book | 240.24 X | ||||
| Price To Sales | 7.23 X | ||||
| Revenue | 36.85 M | ||||
| EBITDA | (166.08 M) | ||||
| Cash And Equivalents | 225.13 M | ||||
| Cash Per Share | 2.32 X | ||||
| Total Debt | 33.83 M | ||||
| Debt To Equity | 0.28 % | ||||
| Book Value Per Share | 0.31 X | ||||
| Cash Flow From Operations | (168.88 M) | ||||
| Earnings Per Share | (0.60) X | ||||
| Total Asset | 226.06 M | ||||
| Retained Earnings | (826.36 M) | ||||
| Current Asset | 71.4 M | ||||
| Current Liabilities | 51.32 M | ||||
About Mersana Therapeutics Performance
By examining Mersana Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Mersana Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Mersana Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates for cancer patients with unmet need. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. Mersana Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 169 people.Things to note about Mersana Therapeutics performance evaluation
Checking the ongoing alerts about Mersana Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Mersana Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mersana Therapeutics is way too risky over 90 days horizon | |
| Mersana Therapeutics appears to be risky and price may revert if volatility continues | |
| Mersana Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 36.85 M. Net Loss for the year was (171.67 M) with loss before overhead, payroll, taxes, and interest of (146.8 M). | |
| Mersana Therapeutics currently holds about 225.13 M in cash with (168.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Mersana Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 95.0% of the company shares are owned by institutional investors |
- Analyzing Mersana Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mersana Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Mersana Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mersana Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mersana Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mersana Therapeutics' stock. These opinions can provide insight into Mersana Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.